Drug intelligence / Profile preview

prulgliptin

Development stage: Unknown
Lead developer: CSPC Pharmaceutical Group
Modality: Small Molecules
Administration: Oral

Overview

Prulgliptin is an orally active, small molecule dipeptidyl peptidase-4 (DPP-4) inhibitor developed by CSPC Pharmaceutical Group for the treatment of type 2 diabetes mellitus. By inhibiting the DPP-4 enzyme, prulgliptin prevents the degradation of incretin hormones, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This leads to increased insulin secretion and suppressed glucagon release in a glucose-dependent manner, effectively lowering blood glucose levels. Prulgliptin is being developed as both a monotherapy and in fixed-dose combinations with other antidiabetic agents like metformin.

Other names: 普鲁格列汀

Targets

DPP7 (Dipeptidyl peptidase 7)DPP9 (Dipeptidyl Peptidase 9)DPP8 (Dipeptidyl peptidase 8)FAP (Fibroblast activation protein alpha)

Beyond the preview

Go deeper on prulgliptin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on prulgliptin.

Explore the full profile